Bolland MJ, Horne AM, Briggs SE, et al. - Because the antiresorptive impact of two annual 4-mg doses of zoledronate in HIV-infected men persisted for at least 5 years after the second dose, researchers ascertained if the impact on BMD and bone turnover persist beyond 10 years. In the original trial, all candidates (known to be alive and living in New Zealand) were requested to attend an additional visit about 12 years after trial entry and 11 years after their second dose of study medication. In all, 25 of the 43 men who were originally enlisted in the trial attended the final visit, representing 25 out of 31 (81%) at the time living and residing in New Zealand. The authors discovered that two annual 4-mg doses of zoledronate affected bone turnover and BMD in males who continued for a minimum of 11 years after the second dose.